At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.
Publication|Articles|October 19, 2026
Pharmacy Practice in Focus: Oncology
- October 2026
- Volume 8
- Issue 7
Onboarding the On-Body: Implementing Subcutaneous Isatuximab via On-Body Injector
Fact checked by: Ron Panarotti
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Advertisement
Advertisement
The advent of frontline quadruplet regimens containing anti-CD38 monoclonal antibodies (mAbs) added to RVd (lenalidomide [Revlimid; Bristol Myers Squibb], bortezomib [Velcade; Takeda Pharmaceuticals], dexamethasone) has improved outcomes for patients with newly diagnosed multiple myeloma (MM) who are transplant eligible and, more recently, those who are transplant ineligible or have deferred transplant. These regimens have increased the likelihood of achieving higher response rates and measurable residual disease negativity, which have translated to significantly improved progression-free survival (PFS) and overall survival. The 2 anti-CD38 mAbs used in this setting are isatuximab (Isa; Sarclisa; Sanofi) and daratumumab (Dara; Darzalex; Janssen Biotech), added to RVd.1
Related to this article
A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
Pharmacists make a difference in patients’ lives through MTM services.
Peptide cancer vaccines target neoantigens to boost T cells, with promising melanoma and pancreatic trials hinting at a new era in immunotherapy.
Each October, the pharmacy profession pauses to recognize technicians' decades-long evolution, from on-the-job trainees to nationally certified health care professionals.
Peer Reviewed
Creating institution-specific, literacy-friendly chemotherapy education sheets resulted in patient education materials with higher readability scores than similar materials from common chemotherapy education sites.
How oncology pharmacy leaders fight burnout with stay surveys, smarter schedules, and recognition—building resilient teams through loss and turnover.
Advertisement
Advertisement